Pharmaceuticals Trends- Partnerships, Licensing, Investments and M&A Deals – Q1 2017

Posted on 2017-08-08 by Mark Hub in Pharmaceuticals // 0 Comments

Market Research Hub

Albany, US, 2017-Aug-08 — /EPR Network/ — Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q1 2017” to its report offerings. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q1 2017.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1277406

The report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q1 2017. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalDatas proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

The pharmaceutical and healthcare industry reported a decrease in the number of deals and an increase in deal values in Q1 2017 with 1,142 deals worth USD95.5 billion, as compared 1,165 worth USD91.4 billion in Q1 2016. On a quarter-on-quarter basis, the number of deals and deal values increased in Q1 2017, when compared to 1,082 deals worth USD84.3 billion in Q4 2016. The pharmaceutical and healthcare industry reported a decrease in upfront payments in licensing agreements with USD731m in Q1 2017, as compared USD1.3 billion in Q1 2016. On a quarter-on-quarter basis, the upfront payments reported a decrease in Q1 2017, when compared to USD1 billion in Q4 2016. Deals in oncology therapeutics market registered an increase with 421 deals in Q1 2017, compared to 356 deals in Q4 2016.

Scope
– Analysis of the market trends for the pharmaceutical industry in the global arena.
– Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and womens health segments.
– Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
– Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
– Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
– Analysis of partnership and licensing deals based on clinical stage of development of products.
– Summary of the pharmaceutical deals globally in the five quarters.
– Information on the top deals happened in the pharmaceutical industry.
– Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
– League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy
– Enhance your decision making capability in a more rapid and time sensitive manner.
– Find out the major deal performing segments for investments in your industry.
– Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
– Identify companies that are aggressively looking to raise capital in the market
– Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
– Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
– Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
– Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
– Identify growth segments and opportunities in each region within the industry.
– Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Read Full Report with TOC: http://www.marketresearchhub.com/report/partnerships-licensing-investments-and-manda-deals-and-trends-in-pharmaceuticals-q1-2017-report.html

Table of Contents:

1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 7
2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q1 2017 10
2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q1 2017 10
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q1 2017 12
2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q1 2017 13
2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q1 2017 14
2.4.1 Johnson & Johnson to Acquire Actelion for USD30 Billion 14
2.4.2 Takeda Pharma Acquires Ariad Pharma for up to USD5.2 Billion in Tender Offer 15
2.4.3 Pfizer Raises USD4.2 Billion in Public Offering of Notes 15
2.4.4 Royalty Pharma Acquires Royalty Stream of Tysabri from Perrigo for USD2.85 Billion 16
2.4.5 Fresenius Raises USD2.7 Billion in Private Placement of Notes 16
3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 17
3.1 Pharmaceuticals & Healthcare, Global, M&A, Q1 2017 17
3.1.1 Top M&A Deals in Q1 2017 18
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q1 2016 – Q1 2017 19
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q1 2017 20
3.2.1 Top Initial Public Offerings in Q1 2017 21

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1277406

About Market Research Hub:

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Matched content

Editor’s pick